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ABSTRACT Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with the
human malignancy Kaposi’s sarcoma and the lymphoproliferative disorders primary
effusion lymphoma and multicentric Castleman’s disease. KSHV establishes lytic in-
fection of monocytes in vivo, which may represent an important cellular reservoir
during KS disease progression. KS tumors consist of latently infected endothelial
cells; however, lytic phase gene products are important for KS onset. Early KS lesion
progression is driven by proinflammatory cytokines supplied by immune cell infil-
trates including T cells and monocytes. KSHV-infected monocytes may supply the
lytic viral products and the inflammatory milieu conducive to KS tumor progression.
To establish successful infection, KSHV extensively modulates the host immune sys-
tem. KSHV antigens activate both innate and adaptive immune responses including
KSHV-specific T cells, but lifelong infection is still established. Programmed death li-
gand 1 (PD-L1) is a prosurvival cell surface protein that suppresses T-cell-mediated
killing. PD-L1 is variably present on various tumor cells and is a targetable marker
for cancer treatment. We show that KSHV infection of human monocytes increases
PD-L1 expression and transcription in a dose-dependent manner. We also saw evi-
dence of lytic gene expression in the KSHV-infected monocytes. Intact KSHV is
needed for full PD-L1 response in human monocytes. KSHV induces a general proin-
flammatory cytokine milieu including interleukins 1, 1, and 6, which have been
implicated in early KS lesion progression. KSHV-mediated PD-L1 increase may repre-
sent a novel mechanism of KSHV-mediated immune modulation to allow for virus
survival and eventually malignant progression.
IMPORTANCE KSHV is the etiologic agent of Kaposi’s sarcoma and the lym-
phoproliferative disorders primary effusion lymphoma and multicentric Castle-
man’s disease. Programmed death ligand 1 (PD-L1) is an immunosuppressive cell
surface marker that inhibits T cell activation. We report that KSHV infection of
primary human monocytes upregulates PD-L1 transcription and protein expres-
sion. Analysis of the cytokine and chemokine milieu following KSHV infection of
monocytes revealed that KSHV induces interleukins 1, 1, and 6, all of which
have been implicated in KS development. Our work has identified another po-
tential immune evasion strategy for KSHV and a potential target for immunother-
apy of KSHV-derived disease.
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Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with the endothelium-derived malignancy Kaposi’s sarcoma (KS) and the B cell lymphoproliferative
disorders primary effusion lymphoma (PEL), multicentric Castleman’s disease (MCD), as
well as cases of germinotropic lymphoproliferative disorder (GLD) (1–4). KS remains the
most common AIDS-defining malignancy and the leading cause of cancer in sub-
Saharan African men (5). KSHV-associated disease primarily manifests in immunocom-
promised patients such as solid organ transplant recipients, HIV-positive patients, and
the elderly (5). A competent immune response is typically sufficient to prevent KSHV-
mediated malignancies in the vast majority of lifelong KSHV infections. However, the
immune system may also aid in early KS lesion progression, since a heavy immune cell
infiltration and a proinflammatory cytokine milieu are present in early KS lesions
and aid in lesion progression (6, 7). Although reconstitution of the host immune
system via highly active antiretroviral therapy (HAART) in AIDS-KS or change of
immunosuppressive regimens in iatrogenic KS often leads to clinical regression of
KS (6), an improper immune response in immune reconstitution inflammatory
syndrome (IRIS) during HAART-initiated repopulation of CD4 T cells can lead to KS
lesion progression (6). Therefore, a proper balance of immune response is vital for
control of KSHV and prevention of its downstream malignancies. Programmed
death ligand 1 (PD-L1) (also called B7-H1 and CD274) is an immunomodulatory cell
surface protein, which interacts with the programmed death 1 (PD-1) (CD279)
receptor on activated T, B, myeloid, and natural killer (NK) cells to induce a
suppressive costimulatory signal (8–16). T cell receptor (TCR) signaling is blocked by
PD-1–PD-L1 engagement, which leads to T cell anergy and immune tolerance. PD-L1
is constitutively expressed by a wide range of cells and is important in peripheral
immune tolerance (9, 12, 17–20). PD-L1 is also induced by both type 1 and 2 interferons
(19, 20). Chronic PD-1–PD-L1 interaction results in T cell exhaustion and is utilized by
many viruses, including HIV, hepatitis C virus (HCV), and HBV, to induce an immune
tolerant environment (21–23). A specific T cell response is generated to both KSHV
latent and lytic antigenic proteins; however, it is apparent that KSHV-infected cells are
not effectively cleared, since the virus establishes lifelong infection (24, 25). In addition
to infections that induce increases in the PD-1–PD-L1 axis, cancer cells also upregulate
PD-L1 levels (26–30). Importantly, therapeutic antibodies disrupting the PD-1–PD-L1
interaction have shown efficacy in treating PD-L1-overexpressing cancers (31–34).
KSHV is tropic for monocytes both in vivo and in vitro (35–40). Within KS, the primary
tumor is composed of latently infected spindle cells combined with a small subset of
lytic cells and inflammatory cell infiltrate. KS tumor progression is theorized to be
dependent on proinflammatory cytokines. Cytokine involvement is suggested by the
high dependency of KS spindle cells in vitro on cytokines for growth, exposure to these
required cytokines in vitro induces a morphological shift to the classic spindle KS shape
in endothelial cells, and high levels of proinflammatory cytokines including interleukin
1 (IL-1), IL-1, and IL-6 are found within the KS tumor microenvironment (7). The
contribution of KSHV lytic replication to KS tumor development was demonstrated
when AIDS patients were administered ganciclovir, a lytic phase inhibitor of herpesvi-
ruses, and KS incidence was significantly reduced (41). The lytic phase of KSHV infection
results in the production of infectious virus and also induces the expression of all viral
genes, which include viral homologues of cytokines and chemokines (5). Thus, lytic
infection may be both inducing inflammation and reseeding tumor cells. Monocytes
have been found to support KSHV lytic replication and may represent an important
reservoir of virus during KS development (36). KS is the most common AIDS-defining
cancer and coinfection of monocytes with KSHV and HIV leads to higher HIV replication
(5, 37). Therefore, monocytes may play an important role in KSHV-associated disease.
Previous studies have found that KSHV-positive PEL and GLD tumor cells are highly
PD-L1 positive (42, 43) and that KS patient NK cells have increased PD-1 levels (44).
Other infection events such as chronic infection of HIV and HBV also result in increased
PD-L1 levels on CD14 monocytes, which may establish an immune tolerant environ-
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ment to allow for long-term infection (23, 45). A similar situation may be occurring with
KSHV infection.
KSHV modulates the host immune system to successfully establish lifelong infection.
During both the lytic and latent phases of KSHV’s life cycle, immunomodulatory genes
are expressed. KSHV is able to disrupt a wide range of immune responses from innate
immune sensing molecules, including Toll-like receptors, Nod-like receptors, and reti-
noic acid-inducible gene I product (RIG-I)-like receptors, to adaptive immune mecha-
nisms, such as downregulation of major histocompatibility complex I (MHC-I) antigen
presentation and expression of immunosuppressive viral cell surface homologues (46).
Increased expression of PD-L1 may represent a novel pathway of immune suppression
facilitated by KSHV.
We report that de novo infection of primary monocytes with KSHV induces increased
PD-L1 levels through increased PD-L1 gene transcription. We also found evidence of
lytic gene expression in the KSHV-infected monocytes. UV-inactivated KSHV failed to
induce similar PD-L1 increases, suggesting that infection with KSHV is driving PD-L1
increase. Infection with increasing doses of KSHV correlate with increasing PD-L1
surface expression and transcription. KSHV-infected monocytes produce a general
proinflammatory response similar to the KS tumor microenvironment cytokines with
enrichment of IL-1, IL-1, and IL-6 compared to uninfected control cells. Overall, these
data suggest that KSHV infection of monocytes may promote an immune tolerant
environment and a cytokine milieu potentially allowing for both viral evasion and
oncogenic progression.
RESULTS
KSHV infection upregulates PD-L1 surface expression on monocytes. As KSHV
has evolved multiple strategies for evasion of the immune response, we hypothesized
that KSHV may modulate the PD-1–PD-L1 pathway. Monocytes are permissive for KSHV
infection (35) and express PD-L1 (11). Therefore, we investigated whether KSHV infec-
tion of monocytes could alter expression of PD-L1. Primary human monocytes were
isolated using negative selection from human peripheral blood mononuclear cells
(PBMCs). The monocytes were then infected with intact KSHV, ultraviolet (UV) light-
inactivated KSHV, or PBS (mock infected). Cells were harvested at 24, 48, or 72 h
postinfection (hpi), and PD-L1 levels were measured via cell staining and flow cytom-
etry. This analysis was performed with 14 different human donors at multiple time
points after KSHV infection. CD14-positive monocytes show increased PD-L1 surface
expression following KSHV infection at 24 hpi through 72 hpi (Fig. 1A). Intact KSHV is
necessary for the increase in PD-L1 following infection (Fig. 1B). Whole-cell lysates
harvested at 36 hpi show increased PD-L1 protein expression following KSHV infection
compared to mock-infected cells (Fig. 1C). We consistently observed an increase in
PD-L1 protein expression in CD14-positive cells compared to mock-infected cells from
all donors (Table 1). The fold increase varies from 5.8-fold to more than 106-fold
depending on the individual donor. These data suggest that infection of monocytes
with KSHV results in a rapid and sustained increase in expression of the immunomodu-
latory protein PD-L1.
As PD-L1 expression on the surfaces of monocytes increased in KSHV-infected cells
compared to mock-infected cells, we hypothesized that this may be due to an increase
in PD-L1 transcription. RNA was harvested from mock-infected and KSHV-infected cells
at 24, 48, and 72 h, reverse transcribed, and subjected to real-time PCR (RT-PCR) to
assess PD-L1 transcript levels. All PD-L1 transcript levels were normalized to -actin
message. PD-L1 transcription peaks at 24 h postinfection and then tapers off at 48 and
72 h postinfection (Fig. 2A). The general trend was observed for 14 donors with various
infectious doses and time points analyzed; 24 hpi (n  14), 48 hpi (n  9), and 72 hpi
(n  8). These data suggest that infection with KSHV increases PD-L1 transcription at
early time points and that while the protein level (Fig. 1C) remains high, message levels
decrease over time.
KSHV Increases PD-L1 and Proinflammatory Cytokines ®
September/October 2017 Volume 8 Issue 5 e00917-17 mbio.asm.org 3
To ensure that the increase in PD-L1 message and level of expression is due to
primary KSHV infection, the level of KSHV RNA present inside the infected monocytes
was assessed. RNA was extracted from monocytes at 48 h after infection with either
intact KSHV or UV-inactivated KSHV. The levels of viral interleukin-6 (vIL-6) were
quantified via real-time PCR for message levels at 48 h postinfection (47). KSHV vIL-6 at
48 hpi showed increasing levels correlated with increasing dosages of intact KSHV
(Fig. 2B) (24 and 72 hpi data not shown). KSHV transcripts were virtually undetected in
mock-infected or UV-inactivated KSHV-infected cells.
KSHV displays lytic infection at 48 h postinfection in monocytes. Similar to other
herpesviruses, KSHV infection displays either a latent or lytic life cycle (48). We infected
primary human monocytes with KSHV, and cells were harvested at 48 hpi. We deter-
mined the levels of various lytic KSHV transcripts via RT-PCR including the following:
vIL-6, open reading frame 39 (ORF39), ORF57, ORF59, K8.1, viral interferon regulatory
factor 1 (vIRF1) and replication and transcription activator (RTA) (48–50) (Fig. 3A).
Further, we determined the protein level of the lytic KSHV ORF45 protein via immu-
FIG 1 PD-L1 protein expression following KSHV infection. Primary human monocytes were isolated from buffy coats, and 5  106
monocytes per well were infected with KSHV (2 109 genomes/well). The cells were harvested at 24, 48, or 72 h postinfection and stained
for CD14 and PD-L1, and expression of these markers was measured by flow cytometry. Cells were gated on forward scatter, side scatter,
and CD14. Histograms indicate the gate of PD-L1-positive cells with the gray-shaded histogram showing the percentages of mock-
infected cells and the histogram outlined by the thick black line showing the percentages of KSHV-infected cells. (A) Representative
histogram of the general trend from 14 independent donors. (B) Percent CD14 cells expressing PD-L1 at 24 to 48 h after exposure to
KSHV versus mock treatment or exposure to UV-treated KSHV (UV) for 48 h. The values between the KSHV-infected and mock-infected cells
or the KSHV-infected and UV-inactivated KSHV-infected cells were significantly different (P  0.00001) by ANOVA posthoc comparison
adjusted for multiple comparison by Tukey’s honestly significant difference test (HSD). (C) PD-L1 protein expression by immunoblotting
at 36 h after KSHV infection of 3  106 monocytes per well.
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noblotting (51) (Fig. 3B). The presence of both lytic transcripts and protein are highly
suggestive of active KSHV lytic infection.
PD-L1 response is dependent on infection with intact KSHV.We investigated the
ability of UV-inactivated KSHV virions to increase PD-L1 levels at 48 h postinfection
TABLE 1 Percentages of cells expressing PD-L1 following KSHV primary infection at 24,
48, and 72 h postinfection
Time point (hpi)
% cells expressing PD-L1 in:
Fold changeMock-infected cells KSHV-infected cells
24 h 5.26 58.3 11.08
1.93 41.1 21.30
4.33 34.3 7.92
5.43 89.6 16.50
3.58 85.8 23.97
4.53 88.9 19.62
3.77 92.3 24.48
12.1 85.4 7.06
2.06 76.7 37.23
2.13 28.7 13.47
7.94 46.0 5.79
6.67 56.4 8.46
4.31 78.3 18.17
48 h 4.61 74.6 16.18
7.33 63.5 8.66
0.23 24.4 106.09
5.03 78.3 15.57
3.78 62.4 16.51
5.62 90.4 16.09
72 h 4.50 54.1 12.02
6.60 88.2 13.36
4.38 86.8 19.82
2.37 44.1 18.61
2.10 77.7 37.00
4.68 32.0 6.84
7.22 41.7 5.78
4.47 82.4 18.43
FIG 2 Levels of PD-L1 transcripts increase following KSHV infection. Human monocytes (5  106
monocytes/well) were infected with KSHV (1  109 genomes/well) (A and B) or UV-inactivated KSHV (B)
for 24, 48, or 72 h. Total KSHV genomes were calculated prior to infection for panel B, and different
amounts of KSHV genomes per well (5.6  107, 2.5  108, 5.6  108, and 1.7  109) were used.
UV-inactivated KSHV genomes used were 1.7 109 per well. At each time point, a mock-infected control
was also harvested. After harvest, RNA was isolated from cells and reverse transcribed, and cDNA levels
were measured through quantitative real-time PCR to assess either PD-L1 (A) or KSHV-encoded viral
interleukin-6 (vIL-6) (B) message levels. RNA levels were normalized to -actin and are represented as fold
increase over mock-infected values at each time point. The data are representative plots of single
experiments but represent the general trend of 11 donors for PD-L1 (24 hpi) transcript levels and 5
donors for vIL-6 (48 hpi) transcript levels. Error bars represent standard deviations of the fold change
values for three technical replicates.
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(Fig. 4A). PD-L1 surface protein levels were increased by intact KSHV virions; however,
UV-inactivated KSHV did not induce an increase in PD-L1 similar to the level induced by
intact KSHV (Fig. 4A). Infection with UV-inactivated KSHV resulted in PD-L1 transcript
levels similar to those of mock-infected cells (Fig. 4B).
KSHV-mediated increase in PD-L1 expression is dose dependent. We next inves-
tigated whether there was a correlation between the dose of virus used for infection
and the levels of PD-L1 and cytokine production. Monocytes isolated from the same
donor were infected with a low dose of KSHV (3  108 genomes/well) and a high dose
of KSHV (2.1  109 genomes/well). At both 24 and 72 h postinfection, the cells that
were infected with the higher dose of virus expressed higher levels of PD-L1 on the cell
FIG 3 KSHV establishes lytic infection of human monocytes at 48 h postinfection. Human monocytes (5 
106 monocytes/well) were infected with KSHV (8.7  107 genomes/well) for 48 h. At each time point, a
mock-infected control was also harvested (A and B). (A) After harvest, RNA was isolated from cells and
reverse transcribed, and cDNA levels were measured using quantitative real-time PCR to assess KSHV-
encoded viral interleukin-6 (vIL-6), open reading frame 39 (ORF39), ORF57, ORF59, K8.1, viral interferon
regulatory factor 1 (vIRF1), and replication and transcription activator (RTA) message levels as normalized
to -actin and represented as fold increase over mock-infected values. Error bars represent the standard
deviations of fold change values for three technical replicates. (B) Immunoblot of KSHV viral protein ORF45
at 48 h postinfection. The data are representative plots of single experiments but represent the general
trend of at least two (A) and four (B) independent donors and experiments.
FIG 4 Infection with intact KSHV results in increased PD-L1 expression. Primary human monocytes (5  106 monocytes/well) were infected with
either intact or UV-inactivated KSHV (9.5  108 genomes/well) and harvested at 48 h postinfection (A and B). (A) Cells were gated on forward
scatter, side scatter, and CD14. Histograms indicate the percentages of PD-L1-positive cells with the percentages for mock-infected cells,
UV-inactivated KSHV-infected cells, and high-dose KSHV-infected cells. The results shown in panel A are representative of the results from four
independent human donors. (B) RNA was isolated from cells and reverse transcribed, and cDNA levels were measured through quantitative
real-time PCR to assess PD-L1 message levels. RNA levels were normalized to -actin and represented as fold increase over mock-infected
monocytes. Error bars represent standard deviations of fold change values for three technical replicates. The data are representative of the general
trend of four independent donor experiments.
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surface than the cells infected with the low dose of virus (Fig. 5A). This effect was
observed with multiple donors (Fig. 5B). To better understand the general monocytic
PD-L1 response to herpesviruses, we also infected monocytes with herpes simplex virus
1 (HSV-1) at multiplicities of infection (MOIs) of 0.02 and 0.2. The PD-L1 response to
HSV-1 showed a similar dose-dependent increase to increasing HSV-1 doses (Fig. 5C).
Moreover, an increase in PD-L1 protein was accompanied by an increase in PD-L1
message in infected cells compared to mock-infected cells (Fig. 5D). Again, the message
increase was variable between donors, but the general trend remained the same over
7 donors. These data suggest that increased doses of KSHV and HSV-1 correlate with
the increase in PD-L1 transcription and protein production.
Multiple cytokines and chemokines are induced in monocytes following KSHV
infection. PD-L1 expression can be driven by cytokine signaling pathways (52). Further,
cytokines and chemokines play a role in KS tumor progression, particularly early in
lesion development (6, 7). Therefore, we determined the production of a panel of
cytokines and chemokines by KSHV-infected monocytes at 24, 48, and 72 h postinfec-
tion. The average cytokine levels in 14 donors at 24 h postinfection are shown in
Table 2. At first glance, the levels of nearly all of the 35 analytes tested were increased
in response to KSHV infection in monocytes compared to mock-infected monocytes
(Table 2). In time course experiments, cytokines that were increased at 24 h postinfec-
tion exhibited higher levels at 48 and 72 h (data not shown). Cytokines that were
increased at lower levels of KSHV infectious dose exhibited higher levels at higher levels
of infectious dose (data not shown). Yet, there was also considerable random variation
among donors, as would be expected for experiments with primary cells. To account for
the random variation and experimental variation, we used multivariate analysis of
variance (ANOVA). To account for multiple comparisons, we used Dunnett’s posthoc
test on fold enrichment scores calculated on matched infected and mock-infected cells
from the same donor. Furthermore, the data were Z standardized to allow comparison
FIG 5 Increase in PD-L1 expression is dose dependent. Primary human monocytes (5  106 monocytes/well) were infected with a low dose of KSHV (3 
108 genomes/well) or a high dose of KSHV (2.1  109 genomes/well) or mock infected and harvested at 24 and 72 h postinfection. (A and B) Cells were
stained for CD14 and PD-L1, and expression of these markers was measured by flow cytometry. Cells were gated on forward scatter, side scatter, and CD14.
Histograms indicate the gate of PD-L1-positive cells with percentages for mock-infected cells, low dose of KSHV-infected cells, and high dose of
KSHV-infected cells shown. Panels A and B show representative data from donors from seven independent experiments. (C) Monocytes from a donor were
infected with low-dose HSV-1 (MOI of 0.02) and high-dose HSV-1 (MOI of 0.2). (D) RNA was isolated from mock- and KSHV-infected cells and reverse
transcribed, and cDNA levels were measured through quantitative real-time PCR to assess PD-L1 message levels. RNA levels were normalized to -actin and
represented as fold increase over the values for mock-infected monocytes. Error bars represent standard deviations of the fold changes for three technical
replicates. The data are representative of the general trend of seven independent donor experiments.
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across different ranges of responses. Figure 6A shows the relative response on the
horizontal axis compared to eotaxin, which did not change in any of the experiments;
epidermal growth factor (EGF), alpha interferon (IFN-), IL-1, IL-1, IL-6, IL-15, IL-17F,
and IL-2 receptor (IL-2R) and the chemokines IP-10 (interferon-inducible protein of 10
kDa), MIP-1 (macrophage inflammatory protein 1), MIP-1, RANTES (regulated on
activation, normal T cell expressed and secreted), and alpha tumor necrosis factor
(TNF-) changed significantly. Raw concentrations for significantly changed cytokines
are shown in Fig. 6B for each of the donors. The changes in IL2R and IL-17F were
minimal but consistent across donors and conditions. IL-10 increased in about half of
all donors. Whether IL-6, MIP-1, MIP-, or RANTES Luminex beads exhibit cross-
reactivity to the respective viral homologues is not known.
Interestingly, the levels of nearly all of the 35 analytes tested were increased in
response to KSHV infection in monocytes compared to mock-infected cells (Table 2).
Monocyte chemotactic protein 1 (MCP-1) was included in the assay plate; however,
regardless of conditions, readings regularly exceeded upper threshold and were ex-
cluded from analysis. Finally, KSHV increases IP-10 at each time point (Table 2), which
correlates with our previous report that KSHV can activate Toll-like receptor 3 (TLR3),
resulting in the induction of IP-10 downstream of TLR3 signaling (39, 53).
DISCUSSION
In this report, we show that KSHV infection of human primary monocytes results in
an increase in PD-L1 expression. This increase was at the transcriptional level, and
TABLE 2 Average increase in cytokines and chemokines 24 h after KSHV infection
Cytokine or
chemokinea
Avg level (pg/ml) of cytokine or chemokine in:
Fold changeMock-infected cells KSHV-infected cells
FGF-Basic 14.60 21.01 1.44
IL-1 29.02 195.31 6.73
G-CSF 70.86 166.38 2.35
IL-10 4.11 29.95 7.29
IL-13 9.68 19.18 1.98
IL-6 61.36 1,479.86 24.12
IL-12 16.56 30.87 1.86
RANTES 185.34 636.82 3.44
Eotaxin 0.58 0.79 1.35
IL-17A 2.55 5.22 2.04
MIP-1 1,227.75 5,712.83 4.65
GM-CSF 0.56 3.10 5.57
MIP-1 2,356.85 8,056.80 3.42
IL-15 35.06 150.26 4.29
EGF 14.18 60.95 4.30
IL-5 0.85 2.46 2.91
HGF 84.61 154.75 1.83
VEGF 4.18 5.82 1.39
IL-1 31.48 392.39 12.46
IFN- 2.37 4.02 1.69
IL-17F 43.17 112.89 2.62
IFN- 37.28 73.32 1.97
IL-9 1.36 3.56 2.62
IL-1ra 2,676.17 3,683.13 1.38
TNF- 25.26 149.10 5.90
IL-3 6.22 17.14 2.76
IL-2 1.28 4.29 3.36
IL-7 10.54 31.28 2.97
IP-10 112.69 603.13 5.35
IL-2R 66.42 159.30 2.40
IL-22 32.88 53.35 1.62
MIG 9.51 24.41 2.57
IL-4 9.47 20.65 2.18
IL-8 27,310.93 29,531.38 1.08
aFGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-
macrophage colony-stimulating factor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; VEGF,
vascular endothelial growth factor; MIG, monokine induced by gamma interferon.
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although transcript levels decreased over time, protein levels remain increased at least
until 72 h after primary infection with KSHV. We show that at 48 h postinfection of
monocytes, KSHV expresses multiple lytic transcripts and the lytic protein ORF45,
suggesting establishment of an overall lytic phase of infection. Cells that were exposed
to increasing amounts of virus exhibited increased KSHV vIL-6 transcription as well as
increased PD-L1 transcription and protein expression. In addition to an increase in
PD-L1 expression, infected cells also increased production of a variety of generally
proinflammatory cytokines and chemokines. Together these data suggest that KSHV
induces an immune response in cells and one of the potential mechanisms that KSHV
may utilize to decrease immune responses is through upregulation of the immuno-
modulatory protein PD-L1.
KSHV-mediated expression of PD-L1 may be an additional mechanism among many
already identified for KSHV evasion of host immune responses. It is critical that KSHV
avoid detection in order to maintain lifelong infection within the host. To this end,
mechanisms for blockade of many major immunological pathways have already been
identified including the host complement system, type I interferons, Toll-like receptors,
Nod-like receptors, and cytosolic DNA sensors (54). For many of these pathways, KSHV
encodes homologues of cellular proteins which inhibit the pathway such as vIL-6,
FIG 6 Cytokine response following KSHV infection. Supernatants from KSHV-infected and mock-infected monocytes were harvested at 24, 48, and 72 h
postinfection. Supernatants were precleared and then subjected to the human cytokine magnetic 35-plex panel. The average raw values (in picograms per
milliliter) of 35 analytes were measured. (A) Multivariate analysis after individual enrichment compared to matched mock value for the same donor was
calculated, and data were Z standardized. The relative response on the horizontal axis compared to eotaxins is shown, which did not change in any of the
experiments after adjustment for multiple comparisons by Dunnett’s posthoc test. The 95% confidence intervals (95% CI) of the response variables are also
shown by the bars. 95% CIs that do not include zero are considered significant at P  0.05. (B) A box-and-whisker plot of cytokine levels in picograms per
milliliter on the vertical axis in the supernatant of KSHV-infected and mock-infected monocytes for a group of cytokines that significantly and consistently
increased upon KSHV infection. Note that the vertical axis is on a log10 scale. The horizontal axis indicates the different donors. The donors are ordered by mean
enrichment to KSHV infection and not by unique identifier. The median values (horizontal bars), first and third quartile boundaries (boxes), and the 1.5
interquartile ranges (vertical bars) are shown for the cytokines measured shown at the top of each subpanel. Blue indicates mock-infected samples, and red
indicates KSHV-infected samples. Note that some donors were exposed to different concentrations of virus, and measurements were taken at different time
points (24, 48, and 72 h) after infections. These are aggregated here and explain some of the variation. The other 23 analytes in the human cytokine magnetic
35-plex panel did not show consistent changes upon KSHV infection. MCP-1 was excluded from the analysis, as the readings were consistently above the upper
limit of the assay. A total of 14 independent donors were used.
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CD200, and vIRFs. KSHV also expresses some mechanisms to evade adaptive immune
responses, such as downregulation of MHC-I (54).
The role of PD-1–PD-L1 in acute infection is not as widely studied as in the chronic
infection setting (55). Our data examine PD-L1 modulation during acute infection. Due
to the fact KSHV establishes lifelong infection in the host, this means that primary
infection of naive cells takes place sporadically throughout the life of the host following
bouts of viral reactivation from latency (5). Spontaneous production of viral progeny
likely results in periodic infection of naive cells such as monocytes. Although our data
show that PD-L1 levels increase in acute KSHV infection, it is possible that repeated
primary infection may result in chronic PD-L1 upregulation in monocytes. Our data also
reveal a potential mechanism of host evasion utilized by KSHV to establish infection. A
previous report has shown that KS patient NK cells have increased PD-1 surface
expression and show an exhausted phenotype upon stimulation in vitro (44). Further,
inflammatory infiltrates within the KS tumor microenvironment were shown to express
PD-L1 (44). As monocytes are a common infiltrate of KS tumors, our data suggest that
KSHV primary infection of monocytes may be in part contributing to increases in PD-L1
expression and downstream PD-1–PD-L1-induced NK cell exhaustion. Further, KS tumor
progression is highly dependent on inflammatory cytokines in the tumor microenvi-
ronment. We report that KSHV induces an overall proinflammatory cytokine milieu
including IL-1, IL-1, and IL-6, which have all been reported to be important for
KSHV-derived malignancies (6, 7). Finally, previous reports have also shown that PEL
and GLD tumor cells can display increased PD-L1 expression (42, 43).
As PD-L1 and PD1 are overexpressed in a subset of cancers and therapies to block
these pathways have helped to reduce tumor burdens, expression of PD-L1 in KSHV-
infected cells could be of great interest to reduce KSHV persistence and associated
malignancies. Further investigation of KSHV-modulated PD-L1 expression may reveal
individual viral genes responsible for upregulating PD-L1 and potential mechanisms for
targeted treatment of KSHV-associated cancers.
MATERIALS AND METHODS
Monocyte isolation, virus generation, and infection. Human monocytes were isolated from buffy
coats (Gulf Coast Regional Blood Center) using the monocyte isolation kit II (Miltenyi Biotec) according
to the manufacturer’s instructions. The CD14-positive monocytes were assayed for purity, and in all
experiments, only a 85% pure monocyte population was used. The resulting monocytes were plated
into six-well dishes at 5  106 cells/well in RPMI medium.
Kaposi’s sarcoma-associated herpesvirus (KSHV) was isolated from iSLK.219 cells harboring latent
recombinant KSHV.219 (rKSHV.219) (56). iSLK.219 cells were maintained in Dulbecco modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Cellgro), 1% penicillin and strepto-
mycin (Pen-Strep), G418 (250 g/ml), hygromycin (400 g/ml), and puromycin (10 g/ml) (56). To
produce infectious virions, the medium was changed to DMEM containing 1% Pen-Strep, 10% FBS, and
3 g/ml doxycycline, and 1 mM sodium butyrate (56). After 72 h, supernatant was harvested, and cell
debris was pelleted and filtered through a sterile 0.45-m filter. Virus was concentrated as previously
described (57). UV inactivation of KSHV was performed as previously described (39).
Human monocytes were centrifuged with a range of KSHV doses from 4.2  107 to 7.8  109
genomes/well and 10 g/ml Polybrene in serum-free RPMI medium at 2,500 rpm for 90 min at 30°C as
previously described (39). Mock-infected cells were treated with an equivalent volume of phosphate-
buffered saline (PBS), the buffer utilized to concentrate KSHV. Immediately following centrifugation, fetal
bovine serum was added to the medium at a final concentration of 20%. The cells and medium
supernatants were harvested at the times indicated.
Flow cytometry. Cells were stained with CD14 (61D3; eBioscience) and PD-L1 (29E.2A3; BioLegend)
prior to analysis on a MACSQuant VYB cytometer (Miltenyi Biotec) and FlowJo software (Tree Star).
Programmed death ligand 1 (PD-L1) levels were ascertained after gating on CD14.
Immunoblots. Cells were harvested, washed once with PBS, and then lysed. Lysis was mediated
through two separate methods depending on cell number harvested. For samples less than or equal to
5  106 monocytes, cells were resuspended in 40 microliters of a solution of 50 ml NP-40 buffer (0.1%
NP-40, 150 mM NaCl, 50 mM Tris-HCl [pH 8.0] containing a proteinase inhibitor tablet [Roche], 30 mM
-glycerophosphate, 50 mM NaF, and 1 mM Na3VO4) and subsequently frozen and thawed once to
complete lysis. For samples more than 5  106 monocytes, cells were resuspended in 2 Laemmli
sample buffer and simultaneously boiled and vortexed at 1,200 rpm in a ThermoMixer (Eppendorf) until
the pellet was no longer visible (10 to 20 min). Equal amounts of protein were loaded per lane, resolved
by SDS-PAGE, and then transferred to a nitrocellulose membrane. The antibodies used were PD-L1
(E1L3N; Cell Signaling Technology), ORF45 (2D4A5; Thermo Fisher), and actin (C-11; Santa Cruz).
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Nucleic acid isolation and real-time PCR. RNA was isolated using RNeasy Micro kit (Qiagen) and
reverse transcribed with SuperScript III reverse transcriptase (Invitrogen) and oligo(dT) (Invitrogen).
Real-time PCR was performed on a QuantStudio 6 Flex (Applied Biosystems) with PowerUp SYBR green
PCR master mix (Applied Biosystems). The PCR was carried out with 1 cycle of 50°C for 2 min and 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. All fold activations were normalized
to -actin. The primer sequences used for -actin and PD-L1 were as follows: for -actin, forward,
5=-TCATGAAGTGTGACGTGGACATC, and reverse, 5=-CAGGAGGAGCAATGATCTTGATCT (58); for PD-L1,
forward, 5=-GGTGCCGACTACAAGCGAAT, and reverse, 5=-AGCCCTCAGCCTGACATGTC (59). Proprietary
PD-L1 primers (SA Biosciences) were also used and showed threshold cycle (CT) values similar to those
of the aforementioned primers. The forward and reverse primers for cytokines, chemokines, and other
targets follow: for viral IL-6 (vIL-6), forward, 5=-CGGTTCACTGCTGGTATCT, and reverse, 5=-CAGTATCGTT
GATGGCTGGT (47); for open reading frame 39 (ORF39), forward, 5=-GGTTTCCCCTGCTACTTCAA, and
reverse, 5=-CATGCTTGGCCCGATATAC; for ORF57, forward, 5=-TGGACATTATGAAGGGCATCCTA, and re-
verse, 5=-CGGGTTCGGACAATTGCT; for ORF59, forward, 5=-TTGGCACTCCAACGAAATATTAGAA, and re-
verse, 5=-CGGAACCTTTTGCGAAGA; for K8.1, forward, 5=-AAAGCGTCCAGGCCACCACAGA, and reverse,
5=-GGCAGAAAATGGCACACGGTTAC; for replication and transcription activator (RTA), forward, 5=-TGTAA
TGTCAGCGTCCACTC, and reverse, 5=-ATTGCTGGGCCACTATAACC; for viral interferon regulatory factor 1
(vIRF1), forward, 5=-CGTGTCCTTTGGTGAAACTG, and reverse, 5=-TCGGCATTATTTCGAGTACG (49).
Cytokine and chemokine determination. Supernatants were precleared and tested with a human
cytokine magnetic 35-plex panel (Life Technologies) per the manufacturer’s instructions and analyzed
with a MAGPIX instrument (Luminex).
Statistical analysis. All calculations were conducted using the R software package version 3.3.3
“Another Canoe” (released 6 March 2017) with the specific statistical tests indicated. Code is available
upon request.
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